showed a trendp = 0.0628
WST assay revealed that TMAO-activated PBMCs showed a trend toward enhanced cytotoxic activity against AN3CA cells ( p = 0.0628; Fig. 6 H), while no significant effect was observed in HEC-1B cells ( p = 0.6398; Fig. 6 G).
WST assay revealed that TMAO-activated PBMCs showed a trend toward enhanced cytotoxic activity against AN3CA cells ( p = 0.0628; Fig. 6 H), while no significant effect was observed in HEC-1B cells ( p = 0.6398; Fig. 6 G).
We acknowledge that the correlation between the relative abundance of BM and serum TMAO levels in the entire ECa cohort showed a statistical trend ( p = 0.0629; Fig. 2 L) but did not reach the conventional threshold for significance ( p < 0.05).
PBMCs treated with 300 μM TMAO showed increased expression of type I interferon genes, with IFNA1 showing a trend toward significance ( p = 0.0645; Fig. 6 C) and IFNB1 demonstrating significant upregulation ( p = 0.0020; Fig. 6 D).
Serum TMAO levels tended to be higher in the ECa group with CVD history compared to those without; however, this difference did not reach statistical significance ( p = 0.087; Table S2).
In contrast, the 2178 group showed an increasing trend in WST assay ( p = 0.1043 and p = 0.0503, respectively; Figures S20A, S23A) and IL6 gene expression ( p = 0.2568 and p = 0.0830, respectively; Figures S20B, S23C) compared to controls and showed no significant changes in immune cell populations (Figures S23G-S23Q).